Neuro-oncology

The Science of Subgroups: Personalizing the Path Forward

At a Glance

Medulloblastoma is classified into four molecular subgroups: WNT, SHH, Group 3, and Group 4. Doctors use these subgroups, along with genetic markers like TP53 and tumor spread, to classify the disease as standard or high risk to personalize treatment.

One of the most important things to understand after a medulloblastoma diagnosis is that it is not one single disease. In 2021, the World Health Organization (WHO) updated the classification of central nervous system tumors to reflect a major scientific breakthrough: medulloblastoma is actually four distinct diseases, each with its own “molecular fingerprint” ^[1]^[2].

The Four Molecular Subgroups

Doctors now use advanced genetic testing, such as DNA methylation profiling, to identify which of these four groups a tumor belongs to. This “fingerprint” tells the care team how the tumor is likely to behave ^[3]^[4].

WNT: This is the most treatable subgroup, occurring mostly in older children. It has an excellent prognosis, with 5-year survival rates often exceeding 90% ^[5]^[6].
SHH (Sonic Hedgehog): This subgroup is common in infants and adults. Its behavior is highly dependent on a gene called TP53. If an SHH tumor has a TP53 mutation, it is considered high-risk and much more aggressive ^[7]^[8].
Group 3: Found mostly in infants and young children, this is often the most aggressive type. It is frequently associated with MYC amplification—a genetic “gas pedal” that makes the tumor grow and spread rapidly ^[9]^[10].
Group 4: This is the most common subgroup across all ages. It has an intermediate prognosis and researchers are still working to understand its specific genetic drivers ^[11]^[12].

Defining “Risk”: Standard vs. High Risk

Once your child’s team has the molecular subgroup and the staging results (M-stage), they will assign a risk category. This category determines how intensive the treatment needs to be to achieve a cure ^[6]^[13].

Standard (Average) Risk

A child is generally considered “standard-risk” if they meet ALL of the following criteria ^[14]:

Age: Older than 3 years at the time of diagnosis.
M-Stage: M0 (no spread found on the spine MRI or in the spinal fluid).
Residual Tumor: The surgeon removed nearly all the tumor, leaving less than 1.5 cm² behind.
Subgroup/Histology: The tumor does not have high-risk markers like MYC amplification or “large cell/anaplastic” histology.

High Risk

A child is typically considered “high-risk” if ANY of the following are true ^[15]^[6]:

Age: Younger than 3 years (this is because infants cannot safely receive full-dose radiation).
M-Stage: M1, M2, M3, or M4 (any evidence of spread).
Residual Tumor: More than 1.5 cm² of tumor remains after surgery.
Genetic Markers: The presence of a TP53 mutation (in SHH) or MYC amplification (in Group 3).

Why This Matters

This shift to molecular medicine means we no longer use a “one-size-fits-all” approach. For example, children in the WNT group are now being studied for de-escalation, where doctors reduce the amount of radiation to prevent long-term side effects ^[14]. Conversely, children in high-risk groups may receive more intensive chemotherapy or targeted drugs to improve their chances of a cure ^[6]^[16]. Identifying the subgroup is the most critical step in personalizing your child’s care ^[17].

Common questions in this guide

What are the four molecular subgroups of medulloblastoma?

The four molecular subgroups are WNT, SHH, Group 3, and Group 4. Each subgroup has a unique genetic fingerprint that helps oncologists predict tumor behavior and tailor the most effective treatment plan.

What makes a medulloblastoma standard risk?

A standard-risk classification generally means the patient is older than three years, the tumor has not spread, nearly all of the tumor was surgically removed, and no high-risk genetic markers are present.

How do TP53 mutations or MYC amplification affect medulloblastoma?

Genetic markers like a TP53 mutation in SHH tumors or MYC amplification in Group 3 tumors indicate a more aggressive disease. Tumors with these features are classified as high-risk and require more intensive treatments.

Why is DNA methylation profiling used for medulloblastoma?

DNA methylation profiling is an advanced genetic test used to accurately identify a tumor's molecular subgroup. This crucial step allows the care team to avoid a one-size-fits-all approach and personalize therapy based on the tumor's specific biology.

Curated prompts to bring to your next appointment.

1.What is my child's molecular subgroup (WNT, SHH, Group 3, or Group 4)?
2.Was my child's tumor tested for the TP53 mutation or MYC amplification?
3.Based on the residual tumor size and M-stage, is my child considered 'standard-risk' or 'high-risk'?
4.How does my child's molecular subgroup change the 'standard' treatment for their risk category?
5.Was DNA methylation profiling used to confirm the subgroup?

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References (17)

1
Spinal Ependymomas: An Updated WHO Classification and a Narrative Review.
Villanueva-Castro E, Meraz-Soto JM, Hernández-Dehesa IA, et al.
Cureus 2023; (15(11)):e49086 doi:10.7759/cureus.49086.
PMID: 38125233
2
Vismodegib as First-Line Treatment of Mutated Sonic Hedgehog Pathway in Adult Medulloblastoma.
Kian W, Roisman LC, Goldstein IM, et al.
JCO precision oncology 2020; (4()) doi:10.1200/PO.19.00264.
PMID: 32923880
3
Pathology, diagnostics, and classification of medulloblastoma.
Orr BA
Brain pathology (Zurich, Switzerland) 2020; (30(3)):664-678 doi:10.1111/bpa.12837.
PMID: 32239782
4
Advances in the classification of pediatric brain tumors through DNA methylation profiling: From research tool to frontline diagnostic.
Kumar R, Liu APY, Orr BA, et al.
Cancer 2018; (124(21)):4168-4180 doi:10.1002/cncr.31583.
PMID: 30255939
5
Verschlimmbesserung: Craniospinal Radiotherapy Is Essential in WNT Medulloblastoma Patients.
Gottardo NG, Gajjar A
Clinical cancer research : an official journal of the American Association for Cancer Research 2023; (29(24)):4996-4998 doi:10.1158/1078-0432.CCR-23-2331.
PMID: 37823794
6
Efficacy of Carboplatin and Isotretinoin in Children With High-risk Medulloblastoma: A Randomized Clinical Trial From the Children's Oncology Group.
Leary SES, Packer RJ, Li Y, et al.
JAMA oncology 2021; (7(9)):1313-1321 doi:10.1001/jamaoncol.2021.2224.
PMID: 34292305
7
The anti-neoplastic activity of Vandetanib against high-risk medulloblastoma variants is profoundly enhanced by additional PI3K inhibition.
Craveiro RB, Ehrhardt M, Velz J, et al.
Oncotarget 2017; (8(29)):46915-46927 doi:10.18632/oncotarget.14911.
PMID: 28159923
8
Molecular subtypes, prognostic factors, and treatment optimization in pediatric medulloblastoma: a real-world study from China.
Liu J, Sun Y, Li H, et al.
Frontiers in oncology 2025; (15()):1597123 doi:10.3389/fonc.2025.1597123.
PMID: 40809009
9
MYC promotes group 3 medulloblastoma cell proliferation and alleviates ROS-induced cell death by upregulating transketolase.
Wang S, Zhang D, Wang C, Liu Y
Acta neuropathologica communications 2025; (13(1)):139 doi:10.1186/s40478-025-02051-7.
PMID: 40581635
10
Long non-coding RNAs as a predictive markers of group 3 medulloblastomas.
Mutlu M, Tekin C, Ak Aksoy S, et al.
Neurological research 2022; (44(3)):232-241 doi:10.1080/01616412.2021.1975223.
PMID: 34533098
11
The role of DNA methylation in directing treatment in medulloblastoma.
Alsaedi MAH, Strathdee G
Epigenomics 2025; (17(16)):1189-1199 doi:10.1080/17501911.2025.2554570.
PMID: 40904269
12
Medulloblastoma genomics in the modern molecular era.
Kumar R, Liu APY, Northcott PA
Brain pathology (Zurich, Switzerland) 2020; (30(3)):679-690 doi:10.1111/bpa.12804.
PMID: 31799776
13
Risk Stratification of Childhood Medulloblastoma Using Integrated Diagnosis: Discrepancies with Clinical Risk Stratification.
Cho HW, Lee H, Ju HY, et al.
Journal of Korean medical science 2022; (37(7)):e59 doi:10.3346/jkms.2022.37.e59.
PMID: 35191235
14
Childhood medulloblastoma.
Massimino M, Biassoni V, Gandola L, et al.
Critical reviews in oncology/hematology 2016; (105()):35-51.
PMID: 27375228
15
Safety and efficacy of concurrent carboplatin during full-dose craniospinal irradiation for high-risk/metastatic medulloblastoma in a resource-limited setting.
Gupta T, Sinha S, Chinnaswamy G, et al.
Pediatric blood & cancer 2021; (68(5)):e28925 doi:10.1002/pbc.28925.
PMID: 33533557
16
Medulloblastoma Genotype Dictates Blood Brain Barrier Phenotype.
Phoenix TN, Patmore DM, Boop S, et al.
Cancer cell 2016; (29(4)):508-522 doi:10.1016/j.ccell.2016.03.002.
PMID: 27050100
17
Genome-wide methylation and copy number variation analysis of medulloblastoma in a Saudi Arabian pediatric population.
AlKofide A, Arabi T, Ahmed AA, et al.
Annals of medicine and surgery (2012) 2025; (87(10)):6265-6271 doi:10.1097/MS9.0000000000003643.
PMID: 41199913

This page explains medulloblastoma molecular subgroups and risk stratification for educational purposes. Your neuro-oncologist is the best source for interpreting your specific pathology report and determining a treatment plan.

Get notified when new evidence is published on Medulloblastoma.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Guide Contents